secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARTIVION, INC. (AORT)
CIK:        0000784199
Form:       8-K
Filed at:   2024-02-15T23:59:59+00:00
Accession:  0000784199-24-000013
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Artivion Q4 revenue $93.7M (+18% YoY); guides 2024 rev $382-396M
----------------------------------------------------------------

- Q4 revenue $93.7M (+18% GAAP, +15% constant currency); full year $354.0M (+13%).
- Q4 non-GAAP net income $4.6M ($0.11 EPS); adjusted EBITDA $15.3M (+40% YoY).
- Full year net loss ($30.7M); non-GAAP net income $8.4M ($0.20 EPS); free cash flow $11.4M.
- 2024 guidance: revenue $382-396M (+8-12%), adjusted EBITDA $68-72M (+26-34%).
- AMDS PERSEVERE trial met endpoints: 72% mortality reduction, 52% fewer MAEs; FDA PMA expected H2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/784199/000078419924000013/0000784199-24-000013-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/784199/000078419924000013/aort-20240215.htm
  HTML page:      https://secwatch.observer/filing/0000784199-24-000013

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer